Menu Search
Equities

Anebulo Pharmaceuticals Inc

214:FRA

Anebulo Pharmaceuticals Inc

Actions
  • Price (EUR)1.50
  • Today's Change-0.25 / -14.29%
  • Shares traded--
  • 1 Year change-23.86%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 08:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous treatment. Selonabant has completed dosing in a Phase II clinical trial evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication. It is also prioritizing the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with unintentional cannabis poisoning.

  • Revenue in USD (TTM)0.00
  • Net income in USD-8.20m
  • Incorporated2020
  • Employees2.00
  • Location
    Anebulo Pharmaceuticals IncJfl Capital Management1017 Rr 620 S, Suite 107LAKEWAY 78734United StatesUSA
  • Phone+1 (512) 598-0931
  • Websitehttps://www.anebulo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.